Stability indicating method development and validation for the determination of haloperidol and benzhexol by RP-HPLC by M. Syamala et al.
 M. Syamala et al., (2019) Int. J. Res. Pharm. Chem & Analy., 1(2), 52-58 
52   © Rubatosis Publications | International Journal of Research in Pharmaceutical Chemistry and Analysis 
 
 
International Journal of Research in  
Pharmaceutical Chemistry and Analysis 
 
Stability indicating method development and validation for the determination of haloperidol and 
benzhexol by RP-HPLC  
M. Syamala*1, S. Angalaparameswari2, T. Vimalakannan3, C. Sumanjali4, T. Jyotshna5 
1Department of Pharmaceutical Analysis, Krishna Teja Pharmacy College, Tirupati, Andhra Pradesh, India. 
2Department of Pharmaceutical Analysis, Jagan's college of pharmacy, Nellore, Andhra Pradesh, India. 
3Department of Pharmaceutical Analysis, P. Rami Reddy Memorial College of Pharmacy, Kadapa, Andhra Pradesh, India. 
4Department of Pharmacology, P. Rami Reddy Memorial College of Pharmacy, Kadapa, Andhra Pradesh, India. 
5Department of Pharmacology, Annamacharya College of Pharmacy. Rajampet, Andhra Pradesh, India. 
ABSTRACT	 	A	simple,	Accurate,	precise	method	was	developed	for	the	simultaneous	estimation	of	the	Haloperidol	and	Benzhexol	in	Tablet	dosage	form.	Chromatogram	was	run	through	Kromasil	(250mm	4.6mm,	5µ).	Mobile	phase	containing	Buffer	and	Acetonitrile	and	methanol	in	the	ratio	of	48:52	was	pumped	through	column	at	a	flow	rate	of	1.0	ml/min.	Temperature	was	maintained	at	30°C.	Optimized	wavelength	for	Haloperidol	and	Benzhexol	 was	 220nm.	 Retention	 time	 of	 Haloperidol	 and	 Benzhexol	 were	 found	 to	 be	 2.415	min	 and	2.820min.	%RSD	of	the	Haloperidol	and	Benzhexol	were	and	found	to	be	0.6	and	0.2	respectively.	%Recover	was	Obtained	as	98.92%	and	99.60%	for	Haloperidol	and	Benzhexol.	LOD,	LOQ	values	were	obtained	from	regression	equations	of	Haloperidol	and	Benzhexol	were	0.42ppm,	1.27ppm	and	0.04ppm,	0.14ppm	respec-tively.	Regression	equation	of	Haloperidol	is	y	=	24009x	+	38704,	and	of	Benzhexol	is	y	=	40558x	+	2880.	Retention	times	are	decreased	and	that	run	time	was	decreased	so	the	method	developed	was	simple	and	economical	that	can	be	adopted	in	regular	Quality	control	test	in	Industries	
Keywords:	benzhexol;	haloperidol;	RP-HPLC.	
ISSN: Awaiting 
Research Article	
Corresponding	Author	Name:	M.	Syamala	Email: syamalamajjari@gmail.com 	
Article	Info	Received	on:	12-05-2019	Revised	on:	03-06-2019	Accepted	on:	11-06-2019	DOI:	https://doi.org/10.33974/ijrpca.v1i2.77	
 
Copyright© 2019, M. Syamala, et al. S Stability 
indicating method development and validation 
for the determination of haloperidol and ben-
zhexol by RP-HPLC, Production and hosting by 
Rubatosis Publications. All rights reserved.	
INTRODUCTION	The	 phenomenal	 growth	 in	 chromatography	 is	largely	due	to	the	introduction	of	the	versatile	tech-nique	 called	 high-pressure	 liquid	 chromatography,	
which	 is	 frequently	 called	 high-performance	 liquid	chromatography.	Both	 terms	 can	be	 abbreviated	 as	HPLC.	 High-pressure	 liquid-solid	 chromatography	(HPLC)	is	rapidly	becoming	the	method	of	choice	for	separations	and	analysis	in	many	areas.	Most	of	the	samples	that	are	dissolved	can	be	separated	on	some	type	of	HPLC	column[4].	Haloperidol	is	a	psychotropic	agent	indicated	for	the	treatment	of	schizophrenia.	It	also	exerts	sedative	and	antiemetic	activity.	Haloperi-dol	 principal	 pharmacological	 effects	 are	 similar	 to	those	 of	 piperazine-derivative	 phenothiazines.	 The	drug	has	action	at	all	levels	of	the	central	nervous	sys-tem-primarily	at	subcortical	levels-as	well	as	on	mul-tiple	 organ	 systems.	Haloperidol	 has	 strong	 antiad-renergic	and	weaker	peripheral	anticholinergic	activ-ity;	 ganglionic	 blocking	 action	 is	 relatively	 slight.	 It	also	 possesses	 slight	 antihistaminic	 and	 antiseroto-nin	 activity[9].	 Trihexyphenidyl	 is	 an	 anticholinergic	used	 in	 the	 symptomatic	 treatment	 of	 all	 etiologic	groups	 of	 parkinsonism	 and	 drug	 induced	 extrapy-ramidal	 reactions	 (except	 tardive	 dyskinesia).	 Tri-hexyphenidyl	possesses	both	anticholinergic	and	an-tihistaminic	 effects,	 although	 only	 the	 former	 has	been	established	as	therapeutically	significant	in	the	management	of	parkinsonism.		
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Literature	survey	reveals	 that	no	analytical	method	has	been	reported	for	the	estimation	of	Haloperidol	and	Benzhexol.	 So,	 in	 the	present	 study	an	 attempt	have	been	made	to	develop	simple	reverse	phase	high	performance	 liquid	 chromatographic	 methods	 for	quantitative	estimation	of	Haloperidol	and	Benzhexol	in	bulk	drug	and	pharmaceutical	formulations.	It	was	thought	meaningful	to	develop	simple,	precise,	rapid,	efficient,	 reliable	 and	 economical	 RP-	 HPLC	 in	 its	pharmaceutical	 dosage	 form.	 An	 attempt	 has	 been	made	to	develop	and	validate	all	methods	to	ensure	their	accuracy,	precision,	repeatability	and	other	an-alytical	method	validation	parameters	as	mentioned	in	the	ICH	guidelines[20].	
MATERIALS	AND	METHODS	
Chemicals	and	Reagents:	The	chemical	and	materi-als	used	for	the	present	study	are	HPLC	grade.	Meth-anol,	acetonitrile	and	mili	Q	water,	Orthophosphoric	acid	are	procured	from	Rankem,	cipla	private	Ltd.,	In-dia	is	used.	
Instrumentation:	HPLC	system	operated	in	isocratic	mode	was	used	for	the	present	work.	It	was	equipped	with	210nm.	A	Discovery	250	C18	column	(250	x	4.6	mm,	5	μm	particles)	was	used	as	stationary	phase.	A	10μL	 Hamilton	 syringe	 was	 used	 for	 injecting	 the	samples.	De-	gassing	of	the	mobile	phase	was	done	by	using	 an	 sonicator	 (Ultrasonic	 Inc.PTE008).	 A	AFCOSET(ER_200A)	used	for	weighing	the	materials.	Chromatograms	were	recorded	and	integrated	using	Empower	software.		
Optimal	chromatographic	conditions:	The	optimal	chromatographic	 conditions	 used	 for	 HP	 and	 TXH	were:	the	mobile	phase	containing	OPA:	Acetonitrile	:	in	the	ratio	of	48:52%,210nm	detection	wavelength;	Kromasil	C18	column	(250	mm	x	4.6	mm,	5	μm)	 in	isocratic	mode;	 1.0	ml/mn	 flow	 rate;	 1-8	pH	of	 the	mobile	phase,	Temperature	was	maintained	 at	 30c.	The	active	pharmaceutical	 ingredient	 (API)	 concen-trations	 used	 for	 HP	 and	 TXH	 were	25,50,75,100,125,150μg/mL,	 and	 5,10,15,20,25,30	μg/mL,	 respectively.	 The	 runtime	 was	 10	 minutes	and	the	samples	were	injected	using	a	10μL	injector.	
Preparation	 of	 the	 standard	 stock	 solution:	 To	prepare	the	standard	stock	solution,	10	mg	of	HP	and	2mg	TXH	were	weighed	accurately	and	transferred	to	two	separate	25	ml	clean	dry	volumetric	 flasks	and	add	5ml	of	diluent	was	added,	They	were	sonicated	for	5	minutes	to	dissolve	completely.	Sonicated	for	5	minutes	and	made	up	to	the	final	volume	with	dilu-ents.	A	1000	μg/mL	solution	of	each	drug	was	pre-pared.	From	this	0.5	mL	was	further	diluted	to	10	mL	to	get	a	stock	concentration	of	50	μg/mL	solution	for	the	two	drugs.	Required	concentrations	of	 the	solu-tions	were	prepared	by	selective	dilution.	
Method	development	For	the	method	development	several	trials	were	car-ried	out	and	reported.	These	leads	to	the	optimized	chromatographic	 conditions	 for	 the	 estimation	 of	
Haloperidol	and	Benzhexol	in	pharmaceutical	dosage	form.	 Initially	 various	mobile	 phase	 and	 stationary	phase	were	 tested	 in	 an	 attempt	 to	 obtain	 the	best	resolution	for	Haloperidol	and	Benzhexol.	The	mobile	phase	consisting	of	water	pH	adjusted	to	2	with	Or-thophosphoric	acid,	 at	 a	 flow	rate	of	1	ml/min	was	chosen	 for	 method	 development	 and	 validation	 of	Haloperiol	 and	 Benzhexol	 by	 RP-HPLC	method.The	detection	was	selected	at	210nm,	using	reverse	phase	Discovery	250	 c18	 column	Kromocil	 C18(250mm	x	4.6	mm,	5m)column,	the	retention	time	of	Haloperi-dol	 and	Benzhexol	were	 found	 to	 be	 2.415min	 and	2.820min	 respectively.	 The	 total	 run	 time	 was	 6	minutes.	A	mobile	phase	consisting	of	water	pH	ad-justed	to	2	with	Orthophosphoric	acid	was	selected	to	achieve	 maximum	 separation	 and	 sensitivity.	 The	flow	rate	of	1	ml/min	gave	an	optimal	signal	to	noise	ratio	with	reasonable	separation	time.	
RESULTS	AND	DISCUSSIONS		The	standard	stock	solution	for	HP	and	TXH	was	pre-pared	with	appropriate	dilution.	It	was	scanned	in	the	wavelength	region	200	nm	to	400	nm	using	an	ultra-violet	(UV)	-	Visible	spectrophotometer.	The	absorb-ance	 spectrum	 obtained	 was	 analyzed.	 From	 the	spectrum	of	HP	and	TXH,	210	nm	was	selected	as	the	optimum	wavelength	 for	 the	 analysis	 of	 the	 binary	mixture	 using	 RP-HPLC	 method.	 The	 absorption	spectrum	was	shown	in	Figure	with	wavelength	(nm)	as	 X-axis	 and	 absorbance	 (%)	 as	 Y-axis.	 The	meas-ured	wavelength	of	210	nm	was	in	good	Results.	On	the	basis	of	our	experimental	results,	we	conclude	that	 the	 UV	 spectrophotometric	 method	 developed	for	 the	determination	of	minoxidil	was	 found	 to	be	precise,	 accurate	 and	 cost	 effective.	 Hence	 this	method	can	be	used	for	routine	analysis	of	Minoxidil	in	bulk	and	pharmaceutical	dosage	forms.	
Optimized	Method	
Mobile	phase:	Buffer	and	Acetonitrile	were	taken	in	the	ratio	of	48:52.	
Chromatographic	conditions	Column	Used	 :	Kromasil-250x4.6mm,	5µ	Buffer	used	 :	(0.1%)	Ortho	phosphoric	acid		Mobile	phase	 :	OPA:	Acetonitrile	(48:52A)	Flow	rate	 :	1	ml/min		Diluent	 	 :	Water:	ACN	(50:50)	Wavelength	 :	210nm	Temperature	 :	30	ͦ	C	Injection	Volume:	10µl	
Method	 validation:	 There	 were	 nine	 parameters	that	have	to	be	validated	for	the	developed	method	in	accordance	 with	 the	 ICH	 guidelines[20].	 They	 were	specificity,	 linearity,	 precision,	 accuracy,	 recovery,	limit	of	detection,	limit	of	quantification,	robustness	
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and	ruggedness.	In	the	present	work	eight	out	of	nine	parameters	have	been	validated	for	both	the	drug.	
Specificity:	 Specificity	 is	 the	 ability	 to	 assess	 une-quivocally	the	analyte	in	the	presence	of	components	which	may	be	expected	to	be	present.	normally	these	might	 including	 impurities,	 degradants,	 matrix,	etc.An	 investigation	 of	 specificity	 should	 be	 con-ducted	during	the	validation	of	tests,	the	determina-tion	of	 impurities	and	assay.	The	procedure	used	to	explain	specificity	will	depend	on	the	intended	objec-tive	of	the	analytical	procedure.	
 
Figure 1: Optimized chromatogram of Haloperidol and 
Benzhexol 
Linearity:	Six	 Linear	 concentrations	of	Haloperidol	(25-150ppm)	 and	Benzhexol	 (5ppm	 to	 30ppm)	 are	prepared	and	Injected.	Regression	equation	of	the	the	Haloperidol	 and	 Benzhexol	 are	 found	 to	 be,	 y	 =	24009x	+	38704	and	y	=	40558x	+	2880.and	the	re-gression	co-efficient	was	0.999.	
Table 1: Linearity of Haloperidol and Benzhexol  
S.	
NO	
Haloperidol	 Benzhexol	
Conc	
(µg/ml)	 Area	
Conc	
(µg/ml)	 Area	1	 25	 621246	 5	 203548	2	 50	 1292386	 10	 402630	3	 75	 1876799	 15	 624175	4	 100	 2460943	 20	 832366	5	 125	 2992636	 25	 992570	6	 150	 3631661	 30	 1223431	
Table 2: Peak results of Method Precision 
Injection Haloperidol Benzhexol 
Area Area 
Injection 1 2941236 937857 
Injection2 2918294 934542 
Injection3 2970957 937569 
Injection4 2941274 939844 
Injection5 2949154 936059 
Injection6 2944298 939684 
Average 2944202 937593 
SD 16905.4 2057.7 
%RSD 0.6 0.2 
Accuracy:	The	 accuracy	 of	 an	 analytical	method	 is	the	closeness	of	that	results	obtained	by	that	method	to	the	true	value.	Accuracy	may	often	be	expressed	as	percent	 recovery	 by	 the	 assay	 of	 known	 added	amount	of	analyte.	%Recovery	should	be	in	the	range	of	98.0%	to	102%.	
	
 
Figure 2: Linearity curve of Haloperidol and Benzhexol	
Precision:	The	precision	is	procedure	expresses	the	closeness	of	agreement	(degree	of	scatter)	between	the	 series	of	measurements	obtained	 from	multiple	sampling	of	the	same	homogeneous	sample	under	the	prescribed	conditions.	For	method	precision	studies,	the	standard	solution	was	prepared	at	working	con-centration	and	analysis	was	carried	for	six	injections.	
Detection	 Limit:	 The	 detecting	 limit	 of	 each	 and	every	 analytical	 procedure	 is	 the	 lowest	 amount	 of	analyte	 in	 a	 sample,	which	 can	be	detected	but	not	necessarily	 quantitated	 under	 stated	 experimental	conditions.	 LOD	 values	were	 obtained	 from	 regres-sion	 equations	 of	 Haloperidol	 and	 Benzhexol	 were	0.42ppm,	and	0.04PPm	
Quantitation	Limit:	The	Quantification	limit	of	indi-vidual	analytical	procedure	 is	defined	as	 the	 lowest	amount	of	analyte	in	a	sample,	which	can	be	quanti-tatively	determined	with	suitable	precision	and	accu-racy.	 LOQ	 values	 were	 obtained	 from	 regression	equations	 of	 Haloperidol	 and	 Benzhexol	 were	1.27ppm,	and	0.14PPm.	
Table 3: Results for Robustness 
Parameters Haloperi-dol 
Ben-
zhexol Limit 
Robust-
ness 
FM 1.8 1.6 %RSD 
NMT 2.0 FP 1.1 0.1 TM 1.7 1.5 	
y = 23699x + 72248
R² = 0.999
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Table 4: Accuracy peak results of Haloperidol and Benzhexol 
S.No	
Spiked	level	
of	Stand-
ards	
Pre	analysed	
sample	conc.	
(µg/ml)	
Amount	
added	
(µg/ml)	
Total	amount	
found	
(µg/ml)	
%	
Recov-
ery	
%	
Mean	
H
al
op
er
id
ol
	
	1	 50	%	 100	 50	50	50	 50.16	50.69	50.48	 98.49	98.51	98.16	 	98.38		2	 100	%	 100	 100	100	100	 98.01	98.45	98.15	 98.51	98.45	98.01	 	98.32		3	 150	%	 100	 150	150	150	 149.61	149.65	149.67	 99.58	99.77	99.79	 	99.71	
Be
nz
he
xo
l 
 
1	  50 %	  20	 10 10 10	 9.88 9.93 9.88	 98.49 99.69 98.53	  98.90	
 
2	  100 % 	  20 	 20 20 20	 19.65 19.62 19.68	 98.51 98.51 98.51	  98.28	
 
3	  150 %	  20	 30 30 30	 29.87 29.84 29.60	 99.77 100.07 99.77	  99.25	
Table 5: Assay of Tablet 
S. No. Haloperidol %Assay Benzhexol %Assay 
1 100.12 99.07 
2 98.34 98.75 
3 99.12 99.31 
4 99.12 99.29 
5 99.38 99.10 
6 99.22 98.91 
AVG 99.22 99.07 
STDEV 0.57 0.22 
%RSD 0.57 0.22 
Table 6: Degradation studies of acid results 
Sl.no PeakName RT Area %Area Purity1 Angle 
Purity1 
Threshold USPP latecount USP Tailing 
1 Peak 1 1.622 231454 5.92 - - 4366 1.4 
2 Peak 2 1.880 310877 7.95 - - 3640 1.9 
3 Haloperidol 2.431 2826661 62.28 - - 12942 1.2 
4 Benzhexol 2.849 903299 23.86 5.243 5.825 12987 0.8 
Table 7: Degradation studies of Base Results 
Sl.no PeakName RT Area %Area Purity1 Angle 
Purity1 
Threshold 
USPPlatecount 
 USP Tailing 
1 Peak 1 1.893 144143 5.65   4735 1.3 
2 Peak 2 2.126 140107 5.49   8129 1.3 
3 Haloperidol 2.431 2881033 67.42 0.686 0.728 12894 1.2 
4 Benzhexol 2.850 918274 21.44 3.055 3.919 13779 1.2 
Table 8: Degradation studies of thermal results 
Sl.no PeakName RT Area %Area Purity1 Angle 
Purity1 
Threshold 
USP 
Platecount 
USP 
Tailing 
1 haloperidol 2.425 2943573 75.65 1.066 1.665 13171 1.3 
2 benzhexol 2.819 937377 24.35 3.353 4.093 12325 1.2 
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Robustness:	The	robustness	procedure	is	a	measure	of	its	capacity	to	remain	unaffected	by	small,	but	de-liberate	 variations	 in	 method	 parameters	 and	 pro-vides	an	indication	of	its	reliability	during	normal	us-age.	
System	 Suitability	 Testing:	 The	 system	 has	 to	 be	tested	for	its	suitability	for	the	intended	purpose.	Sys-tem	suitability	testing	is	an	integral	part	of	many	an-alytical	procedures.	The	tests	are	based	on	the	theory	that	 the	 instruments,	 electronics,	 analytical	 proce-dures	and	samples	to	be	analyzed	constitute	an	inte-gral	system	that	can	be	evaluated	as	such.	Parameters	like	plate	count,	tailing	factors,	resolution	and	reproducibility	(%	RSD	retention	time	and	area	for	 six	 repetitions)	 are	 determined	 and	 compared	against	the	specifications	set	for	the	method.	
Assay:	Standard	preparations	are	made	from	the	API	and	Sample	Preparations	are	from	Formulation.	Both	sample	and	standards	are	injected	six	homogeneous	samples.	Drug	 in	 the	 formulation	was	 estimated	by	taking	the	standard	as	the	reference.	The	Average	%	assay	 was	 calculated	 and	 found	 to	 be	 99.22%	 and	99.07%	for	Haloperidol	and	Benzhexol	respectively	
Degradation	studies	
Oxidation:	To	1	ml	of	stock	solution	of	Haloperidol	and	 Benzhexol,	 1	 ml	 of	 20%	 hydrogen	 peroxide	(H2O2)	 was	 added	 separately.	 The	 solutions	 were	kept	for	30	min	at	600c.	For	HPLC	study,	the	resultant	solution	 was	 diluted	 to	 obtain	 100µg/ml&20µg/ml	solution	and	10	µl	were	injected	into	the	system	and	the	chromatograms	were	recorded	to	assess	the	sta-bility	of	sample.	
Acid	Degradation	Studies:	To	1	ml	of	stock	s	solu-tion	 Haloperidol	 and	 Benzhexol,	 1ml	 of	 2N	 Hydro-chloric	 acid	was	 added	 and	 refluxed	 for	 30mins	 at	600c.The	 resultant	 solution	 was	 diluted	 to	 obtain	100µg/ml&20µg/ml	 solution	 and	 10	 µl	 solutions	were	 injected	 into	 the	 system	 and	 the	 chromato-grams	were	recorded	to	assess	the	stability	of	sample.	
	
Degradation	studies	of	acid	results	
Alkali	Degradation	Studies:	To	1	ml	of	stock	solu-tion	Haloperidol	and	Benzhexol,	1	ml	of	2N	sodium	hydroxide	was	added	and	refluxed	for	30mins	at	600c.	The	 resultant	 solution	 was	 diluted	 to	 obtain	100µg/ml&20µg/ml	solution	and	10	µl	were	injected	into	 the	 system	 and	 the	 chromatograms	 were	 rec-orded	to	assess	the	stability	of	sample.	Degradation	studies	of	Base	Results:	
Dry	Heat	Degradation	Studies:	The	standard	drug	solution	was	placed	in	oven	at	105°C	for	6h	to	study	dry	heat	degradation.	For	HPLC	study,	the	resultant	solution	was	diluted	to	100µg/ml	&	20µg/ml	solution	and10µl	were	injected	into	the	system	and	the	chro-matograms	were	 recorded	 to	 assess	 the	 stability	of	the	sample.	
Photo	Stability	studies:	The	photochemical	stability	of	 the	 drug	 was	 also	 studied	 by	 exposing	 the	1000µg/ml&	 &200µg/ml	 solution	 to	 UV	 Light	 by	keeping	the	beaker	in	UV	Chamber	for	7days	or	200	Watt	hours/m2	in	photo	stability	chamber.	For	HPLC	study,	 the	 resultant	 solution	 was	 diluted	 to	 obtain	100µg/ml	20µg/ml	solutions	and	10	µl	were	injected	into	 the	 system	 and	 the	 chromatograms	 were	 rec-orded	to	assess	the	stability	of	sample.	
Degradation	studies	of	thermal	results	
Neutral	Degradation	Studies:	Stress	testing	under	neutral	conditions	was	studied	by	refluxing	the	drug	in	water	for	6hrs	at	a	temperature	of	60º.	For	HPLC	study,	 the	 resultant	 solution	 was	 diluted	 to	100µg/ml&20µg/ml	solution	and	10	µl	were	injected	into	 the	 system	 and	 the	 chromatograms	 were	 rec-orded	to	assess	the	stability	of	the	sample.	
CONCLUSION	The	 study	was	undertaken	 in	order	 to	develop	and	validate	 the	analytical	RP-HPLC	method	 for	estima-tion	 of	 Haloperidol	 and	 Benzhexol	 pharmaceutical	formulations.	Literature	survey	reveals	no	analytical	methods	 have	 been	 reported	 for	 the	 estimation	 of	Haloperidol	and	Benzhexol	in	pharmaceutical	formu-lations.	So	the	was	developed	and	validated	by	means	
Table 9: Degradation studies of water sample results 
Sl.no PeakName RT Area %Area Purity1 Angle 
Purity1 
Threshold 
USP 
Platecount 
 
USP 
Tailing 
1 Peak 1 2.170 199333 5.81   10854 1.0 
2 haloperidol 2.419 2945689 71.29   11908 1.2 
3 benzhexol 2.812 940620 22.90 2.248 2.672 11205 1.2 
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of	accuracy,	precision,	linearity,	LOD	and	LOQ	and	ro-bustness	as	per	ICH	guidelines.	From	this	results	concluded	that	a	simple,	precise,	ac-curate	and	sensitive	RP-HPLC	method	was	developed	for	 the	 simultaneous	 estimation	of	Haloperidol	 and	Benzhexol	pharmaceutical	dosage	form.	This	method	can	be	used	in	quality	control	departments	with	re-spect	to	routine	analysis	for	the	assay	of	the	tablets	containing	Haloperidol	and	Benzhexol.	
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